Angle Health's $2.7B tender: the checks before you sell

The tender is a liquidity event, not a new round

You have a deadline: Angle Health's tender offer lets you sell some of your shares. The trap is treating it like a new round that funds your grant. The rule is to compare after-tax cash at the tender price with the upside you are willing to wait for. The financing was expected to close later in September 2026.

On September 18, 2026, Angle Health secured $600 million in financing at a $2.7 billion valuation, comprising a $200 million Series C and a $400 million tender offer. The $400 million tender offer was twice the size of the $200 million Series C. Vitruvian Partners led the financing, and Town Hall Ventures participated as a new investor alongside Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. A tender offer is a secondary transaction: existing holders sell, and the company does not receive the cash. The primary portion funds the company; the secondary portion gives employee liquidity. The tender price is the exit price for the shares you can sell, not a new funding price for the whole company.

If you miss the window, the next chance may come at a different price, or not at all. Put the decision numbers on a whiteboard before you sign: tender price, strike or cost basis, sellable share count, and after-tax cash. If one is missing, you are guessing.

The four checks turn the offer into a number

• Compare the tender price to your strike price.
• Confirm the fraction of shares you can sell.
• Estimate after-tax proceeds.
• Weigh waiting for a higher round against liquidity risk.

Compare the tender price to your strike price, the amount you pay to buy the shares. The per-share tender price is the number in the offer terms, not the company valuation. For vested options, subtract the strike from the tender price to get the gross spread per share. For RSUs, which are shares granted to you, your cost basis may be lower, so the after-tax number can look different. Write the tender price on the left and your strike on the right. Multiply the difference by the number of shares you can sell. If the spread is thin, the after-tax number may be smaller than it looks. You are ready when you can state your gross spread and the share count that produces it.

Confirm how many shares you can actually sell. Tender offers often limit the number of shares each employee can tender, and some shares may be ineligible because they are unvested, subject to a lock-up, a period when selling is restricted, or reserved for tax withholding. Check whether the offer is pro rata, meaning proportional to your holdings, and whether there is a per-employee cap. Ask whether the company can reduce the number of shares sold if demand is high. Read the offer terms, not just the headline. The mistake is assuming the whole grant is available. It usually is not. You are ready when you know the exact share count you can sell and the pre-tax cash that count produces.

Estimate the after-tax proceeds before you decide. Option exercise or RSU vesting can create ordinary income for many employees, taxed at your regular rates. A later sale can create capital gains, taxed on the profit from selling. Incentive stock options, a common type of employee option, can also trigger alternative minimum tax, a separate federal tax calculation, when exercised. Ask a tax advisor for a number based on your state, holding period, and withholding. Do not use the gross spread as your budget. Tax withholding can be large, and the amount you can actually receive may depend on how you exercise or sell. If you are unsure, get a written estimate before the deadline. The test is a cash figure you can bank, not a gross spread.

Weigh waiting for a higher round against liquidity risk. A stronger company can support a higher future price, but it can also delay your exit or change the terms. Angle Health serves more than 5,000 employers. Angle Health had been profitable on both EBITDA, a common profit measure, and GAAP net income, the bottom line under standard accounting rules, for four straight quarters. Those are useful signs, but they are not a promise of a better tender price. Ask what you would need to see to justify waiting: a higher valuation, a stronger earnings trend, or a clearer path to an exit. If you cannot name the reason, the tender may be the cleaner choice. The test is a reason you can say out loud: why you are selling now, or why you are willing to wait.

The after-tax cash decides the call

If the after-tax cash changes your plan, take it. If it does not, keep the shares and accept the risk of waiting.